The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate

The pan HLA DR-binding epitope improves adjuvant-assisted immunization with a recombinant protein containing a malaria vaccine candidate

Author Rosa, D. S. Google Scholar
Tzelepis, F. Google Scholar
Cunha, M. G. Google Scholar
Soares, I. S. Google Scholar
Rodrigues, M. M. Google Scholar
Institution Universidade Federal de São Paulo (UNIFESP)
Fed Univ Para
Universidade de São Paulo (USP)
Abstract The pan HLA DR-binding epitope (PADRE) has been proposed as a simple carrier epitope suitable for use in the development of synthetic and recombinant vaccines. Using the mouse model, we evaluated whether PADRE could improve adjuvant-assisted immunizations with a recombinant malarial protein containing the 19 kDa C-terminal region of merozoite surface protein 1 (MSP1(19)) that is a Plasmodium vivax vaccine candidate. Initially, the antibody immune response was evaluated in C57BL/6 mice, a mouse strain which develops a strong T cell immune response to PADRE. When administered in distinct adjuvant formulations, antibody titers induced by the recombinant protein His(6)MSP1(19)-PADRE were not significantly different to those generated by complete/incomplete Freund's adjuvant (CFA/IFA) in terms of magnitude, affinity, IgG subclasses and longevity. However, in C57BL/6 mice immunized with the recombinant protein His(6)MSP1(19), strong antibody responses could be generated in the presence of CFA/IFA but not other classes of adjuvants such as CpG ODN 1826 or MPL/TDM. Similarly, in BALB/c mice that do not develop T cells specific for PADRE, the recombinant protein His(6)MSP1(19)-PADRE failed to induce high antibody titers in the presence of adjuvants other than CFA/IFA. Our results indicated that when adjuvants that are not as strong as CFA/IFA are employed, the presence of PADRE greatly improved adjuvant-assisted antibody immune responses induced by a malarial recombinant antigen. Considering the great limitations of adjuvants for human use, our observation may improve the rational design of new vaccine formulations. (C) 2004 Elsevier B.V. All rights reserved.
Keywords pan HLA DR-binding epitope
recombinant vaccines and adjuvants
Language English
Date 2004-04-15
Published in Immunology Letters. Amsterdam: Elsevier B.V., v. 92, n. 3, p. 259-268, 2004.
ISSN 0165-2478 (Sherpa/Romeo, impact factor)
Publisher Elsevier B.V.
Extent 259-268
Origin http://dx.doi.org/10.1016/j.imlet.2004.01.006
Access rights Closed access
Type Article
Web of Science ID WOS:000221166600010
URI http://repositorio.unifesp.br/handle/11600/27709

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account